Amanote Research
Register
Sign In
Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins
doi 10.1021/acs.molpharmaceut.9b00418.s001
Full Text
Open PDF
Abstract
Available in
full text
Date
Unknown
Authors
Unknown
Publisher
American Chemical Society (ACS)
Related search
169. Clinically Adaptable CD19-Specific Chimeric Antigen Receptor
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Characterization of Clinical Grade CD19 Chimeric Antigen Receptor T Cells Produced Using Automated CliniMACS Prodigy System
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Cytokine Release Syndrome and Neurotoxicity After CD19 Chimeric Antigen Receptor-Modified (CAR-) T Cell Therapy
British Journal of Haematology
Hematology
Haemophagocytic Lymphohistiocytosis Has Variable Time to Onset Following CD19 Chimeric Antigen Receptor T Cell Therapy
British Journal of Haematology
Hematology
Comprehensive Report of Anti-Cd19 Chimeric Antigen Receptor T-Cells (Car-T) Associated Non Relapse Mortality (Cart-Nrm) From Faers
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Chimeric Antigen Receptor T-Cells
Cancer Journal
Cancer Research
Oncology
Safety of Allogeneic Hematopoietic Cell Transplant in Adults After Cd19 Targeted Chimeric Antigen Receptor-Modified T-Cell (Car-T) Therapy
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression Upon Drug Administration
Cancer immunology research
Cancer Research
Immunology
Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination With Ibrutinib for Relapsed and/or Refractory CLL
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
